Currently, detailed information on serum CAIX as a biomarker is only available in renal cell cancer patients: Serum CAIX has been shown to serve as a promising marker for therapy monitoring and prediction of prognosis in patients with cancer of the kindney [16]. This evidence concerns the gene CA9 and renal cell adenocarcinoma.